| MRI, CT, and PET/CT for ovarian cancer detection and adnexal lesion characterization. | |
| | |
MedLine Citation:
|
PMID: 20093590 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: The purpose of this article is to describe the role of MR, CT, and PET/CT in the detection of ovarian cancer and the evaluation of adnexal lesions. CONCLUSION: The goal of imaging in ovarian cancer detection is to expeditiously distinguish benign adnexal lesions from those requiring further pathologic evaluation for malignancy. For lesions indeterminate on ultrasound, MRI increases the specificity of imaging evaluation, thus decreasing benign resections. CT is useful in diagnosis and treatment planning of advanced cancer. Although (18)F-FDG-avid ovarian lesions in postmenopausal women are considered suspicious for malignancy, PET/CT is not recommended for primary cancer detection because of high false-positive rates. |
| | |
Authors:
|
Veena R Iyer; Susanna I Lee |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: AJR. American journal of roentgenology Volume: 194 ISSN: 1546-3141 ISO Abbreviation: AJR Am J Roentgenol Publication Date: 2010 Feb |
Date Detail:
|
Created Date: 2010-01-22 Completed Date: 2010-02-25 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7708173 Medline TA: AJR Am J Roentgenol Country: United States |
Other Details:
|
Languages: eng Pagination: 311-21 Citation Subset: AIM; IM |
Affiliation:
|
Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, 02114, USA. viyer@partners.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adnexal Diseases
/
diagnosis*,
radiography,
radionuclide imaging Contrast Media Diagnosis, Differential Female Fluorodeoxyglucose F18 / diagnostic use Humans Magnetic Resonance Imaging* Neoplasm Staging Ovarian Neoplasms / diagnosis*, radiography, radionuclide imaging Radiopharmaceuticals / diagnostic use Tomography, Emission-Computed* Tomography, X-Ray Computed* |
| Chemical | |
Reg. No./Substance:
|
0/Contrast Media; 0/Radiopharmaceuticals; 63503-12-8/Fluorodeoxyglucose F18 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Risk assessment and genetic testing for ovarian cancer.
Next Document: Ultrasound and assessment of ovarian cancer risk.